SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is trending as chatter revolves around anticipation for a HBAR ETF potentially launching soon, generating excitement for institutional investment. Community members are actively discussing potential price targets and loading up on tokens, while highlighting Hedera's strong technology and real-world use cases. Some investors view HBAR as a promising altcoin with long-term growth potential amid broader discussions of market regulation and infrastructure.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community anticipates a massive token burn once the watcher goal is reached, a move seen as beneficial to current holders. Active community members highlight the project's commitment to development and its unique ecosystem, including staking, P2E games, and its media platform Broke Perspective. Some are drawing comparisons to $GME, suggesting a similar potential for a significant surge.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the community discusses the potential impact of a Litecoin ETF, with some anticipating significant price movement and inflows. Conversations revolve around technical analysis, potential market manipulation, and comparisons to other cryptocurrencies. Despite mixed sentiment, many express long-term bullishness.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors anticipate upcoming Q3 earnings, with many predicting a strong report and discussing potential catalysts like future rate cuts and a possible S&P 500 inclusion. The community is buzzing with excitement and analyzing technical indicators, while also debating whether the earnings report is already priced in or if a post-earnings pullback is likely. Overall, there's a strong sense of optimism surrounding SoFi's long-term growth potential as a disruptor in the fintech sector.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals ($BCRX) is trending as discussions revolve around potential catalysts ahead of earnings and the implications of competitor Intellia Therapeutics' ($NTLA) safety concerns, with some seeing this as a positive for BioCryst's HAE treatments. The community is weighing analyst ratings, potential acquisitions, and future growth prospects, while also commenting on the high short interest. Some investors speculate about a potential buyout, while others focus on upcoming catalysts and the overall market conditions.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as investors digest a new partnership with NextEra Energy to restart a nuclear plant, aiming to power Google's AI data centers with carbon-free energy and create jobs in Iowa. The community is also closely watching technical indicators and upcoming earnings, with some anticipating a strong run while others express caution about a potential pullback. Bullish sentiment remains due to Google's AI and cloud initiatives.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics ($NTLA) is trending due to recent news about pausing patient dosing in trials after a participant experienced a liver injury, causing a significant stock drop. Despite the negative catalyst, community members highlight Cathie Wood's ARK Invest's purchase of shares, suggesting a vote of confidence, while others discuss potential sector-wide impacts and future catalysts.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending due to a mix of factors, including JPMorgan raising its price target and anticipation for upcoming earnings. The community is discussing technical setups, potential for further upside, and impact from news like the decertification of an antitrust class action related to the App Store. Broader conversations encompass AI integration, satellite connectivity possibilities, and general market sentiment.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending as the crypto market shows signs of a bullish reversal, with community members anticipating a potential breakout towards new all-time highs. Discussions revolve around upcoming catalysts like potential trade deals and Fed rate cuts, as well as observations about ETH's price action relative to Bitcoin. Some traders are closely watching for staking ETF approvals and the impact of institutional buying, while others express concerns about market manipulation.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending as investors anticipate upcoming earnings, with discussions focusing on the potential impact of recent layoffs, particularly within the corporate sector, and the company's shift towards AI-driven automation for cost efficiency. Community members are weighing whether these cost-cutting measures signal underlying weakness or position Amazon for future growth and margin protection. The potential for a trade deal with China is adding another layer of speculation around the stock's near-term performance.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should Invesco NASDAQ 100 ETF (QQQM) Be on Your Investing Radar?

AstraZeneca (AZN) announced on Wednesday that its late-stage trial of Fasenra in patients with chronic obstructive pulmonary disease (COPD) did not achieve statistical significance in the primary endpoint of controlling flare-ups.COPD, also called Smoker’s Disease, is a debilitating, irreversible, and progressive disease whose exacerbations are life-threatening and can cause irreversible lung damage and even death. According to AstraZeneca, it affects 391 million people globally.The safety and tolerability of the drug in the recent trial were consistent with the known profile of the medicine. The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.astrazeneca.com/media-centre/press-releases/2025/update-on-resolute-phase-iii-trial.html">stated</a> that it will analyze the data further to understand the results.Shares of the company slipped 0.3% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AZN">AZN stock</a> fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume fell from ‘normal’ to ‘low’ levels.<figure class="image"><img style="aspect-ratio:572/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_17_at_7_28_11_AM_png_b16313a518.webp" alt="AZN's Sentiment Meter and Message Volume as of 7:28 a.m. ET on Sept. 17, 2025 | Source: Stocktwits" width="572" height="62"><figcaption>AZN's Sentiment Meter and Message Volume as of 7:28 a.m. ET on Sept. 17, 2025 | Source: Stocktwits</figcaption></figure> The study was aimed at evaluating the efficacy and safety of 100 mg of Fasenra in people with moderate to very severe COPD with a history of frequent COPD exacerbations and an elevated blood eosinophil count. The company enrolled patients in the trial with a history of at least two COPD exacerbations in the year before enrollment and who were current or former smokers. Patients were randomized to receive either a placebo or Fasenra while remaining on their existing therapy.“COPD, which remains a leading cause of death worldwide, is a complex, heterogeneous disease and we continue to advance other promising approaches in our pipeline to address the unmet needs of patients,” company executive Sharon Barr saidFasenra is already used to treat severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis in several countries. According to AstraZeneca, over 150,000 patients worldwide are currently taking Fasenra. In the first half of 2025, Fasenra generated $920 million in revenue, representing an 18% year-over-year increase.Separately, the company also <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.astrazeneca.com/media-centre/press-releases/2025/saphnelo-met-primary-endpoint-in-tulip-sc.html">announced</a> that its late-stage trial evaluating subcutaneous Saphnelo in patients with systemic lupus erythematosus (SLE) met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in disease activity compared to placebo. SLE is an autoimmune disease in which the immune system attacks healthy tissue in the body. It is estimated to impact over 3.4 million people globally.AZN stock is up by 18% this year and down by about 1% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/x4-pharma-to-halve-headcount-amid-efforts-to-complete-neutropenia-trial/chDGnJwRd6P">X4 Pharma To Halve Headcount Amid Efforts To Complete Neutropenia Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the AstraZeneca logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

AstraZeneca Says Asthma Drug Failed Trial In Smoker’s Disease

The company stated that the safety and tolerability of the drug in the recent trial were consistent with the known profile of the medicine, and added that it will analyze the data further to understand the results.

Equity

The company stated that the safety and tolerability of the drug in the recent trial were consistent with the known profile of the medicine, and added that it will analyze the data further to understand the results.


Marvell Technology (MRVL) plunged more than 17% at market open on Friday after issuing weaker-than-expected third-quarter guidance in its fiscal second-quarter report released late Thursday, which drew swift price target cuts and&nbsp;a ratings downgrade from Wall Street.<a href="http://stocktwits.com/symbol/MRVL">Marvell’s stock</a> was among the top trending tickers on Stocktwits at the time of writing. Despite the dip in its stock price, retail sentiment around the company surged to ‘extremely bullish’ from ‘bullish’ with chatter rising to ‘extremely high’ from ‘low’ levels over the past day, according to platform data.Bank of America downgraded&nbsp;Marvell’s stock to ‘Neutral’ from ‘Buy’, lowering its price target to $78 from $90, as per TheFly. The firm cited uncertainty surrounding Marvell’s role in Microsoft’s (MSFT) Maia AI accelerator and its share of Amazon’s (AMZN) next-generation 3nm project.Morgan Stanley trimmed its target on the stock to $76 from $80 while keeping an ‘Equal Weight’ rating. The firm noted that while guidance was largely in line once the sale of Marvell’s automotive Ethernet business was factored in, the data center segment “disappointed.” Morgan Stanley added that it was not surprised by the business’s “lumpiness,” but said it was unexpected that the ASIC full-year outlook continues to decline even as demand for Amazon’s Trainium processors strengthens elsewhere.&nbsp;UBS, which lowered its price target to $95 from $110,&nbsp; also pointed to “lumpiness” in Marvell’s business.&nbsp;Needham echoed similar concerns about Marvell’s next-gen XPU contracts with Amazon and Microsoft as it lowered its price target to $80 from $85, but maintained its ‘Buy’ rating on the stock.Marvell’s stock has fallen more than 41% this year and is down around 7% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-revokes-intel-samsung-sk-hynix-waivers-on-china-chip-equipment/chtTKpgRdNh">US Revokes Intel, Samsung, SK Hynix Waivers On China Chip Equipment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Marvell Hit With Downgrade, Price Target Cuts As Analysts Flag Uncertainty In Microsoft, Amazon AI Deals

Bank of America downgraded Marvell’s stock to ‘Neutral’ from ‘Buy’, lowering its price target to $78 from $90.

3 Reasons Why Nasdaq ETFs Hit a Record High 

The Nasdaq hit a record high despite tariffs, as Apple's $100B U.S. push, Fed rate cut talks and chip exemptions fuel tech optimism.

Nasdaq ETF (QQQM) Hits New 52-Week High

QQQM surges to a new 52-week high, fueled by tech strength and AI-driven earnings momentum in Nasdaq.


Will Nasdaq ETFs Continue Their Rally Going Into Q2 Earnings?

QQQ, QQQM, QQEW, QQQJ and QQQE surge as Nasdaq hits highs on earnings momentum, AI optimism and rate cut hopes.

High-Yield ETFs: Big Payouts, Bigger Trade-Offs?

Here's what investors should know about covered-call single-stock ETFs.

AstraZeneca (AZN) on Friday <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-enters-into-collaboration-with-cspc.html">announced</a> a strategic research collaboration with China-based CSPC Pharmaceuticals Group to advance the development of oral drug candidates with the potential to treat multiple chronic diseases.Under the deal, the companies have also agreed to develop a pre-clinical small-molecule oral therapy for immunological diseases.The research will be carried out by CSPC in Shijiazhuang City and will utilize their AI-driven drug discovery platform, which uses AI to analyse the binding patterns of target proteins with existing compound molecules. The AI also helps conduct targeted optimization with the intent of selecting highly effective small molecules with excellent developability.CSPC will receive an upfront payment of $110 million as part of the agreement, and is eligible to receive up to $1.62 billion in potential development milestone payments and up to $3.6 billion in sales milestone payments.CSPC can also receive potential single-digit royalties based on annual net sales of the products.AstraZeneca, meanwhile, will have the right to exercise options for exclusive licenses to develop and commercialize worldwide candidates identified under the agreement.In March, AstraZeneca announced a $2.5 billion investment in a research and development hub in Beijing. The new agreement will further the company’s presence in China, AstraZeneca said.On Stocktwits, retail sentiment around AstraZeneca stayed within the ‘neutral’ territory over the past 24 hours while message volume rose from ‘low’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:1260/132;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_13_at_7_54_25_AM_png_1341b85d61.webp" alt="AZN's Sentiment Meter and Message Volume as of 7:54 a.m. ET on Jun 13, 2025 | Source: Stocktwits" width="1260" height="132"><figcaption>AZN's Sentiment Meter and Message Volume as of 7:54 a.m. ET on Jun 13, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/AZN">AZN stock</a> is up by about 14% this year but down by nearly 6% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-launches-upgraded-model-s-x-in-us-raises-prices-5000-dollars/chlicMCRRGy">Tesla Launches Upgraded Model S, X In US, Raises Prices On All Variants By $5,000</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

AstraZeneca Inks $5.3B Deal With CSPC Pharma For Developing New Oral Drug Candidate, But Retail’s In No Mood To Cheer

CSPC will receive an upfront payment of $110 million as part of the agreement, and is eligible to receive up to $1.62 billion in potential development milestone payments and up to $3.6 billion in sales milestone payments.

Invesco Exchange-Traded Fund Trust II - Invesco NASDAQ 100 ETF

Will Alphabet ($GOOGL) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

QQQM
Invesco NASDAQ 100 ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest QQQM News

QQQMInvesco NASDAQ 100 ETF